Harmony Biosciences (HRMY) | Financial Analysis & Statements
Harmony Biosciences Holdings, Inc. Small-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
243.8M
Gross Profit
175.2M
71.88%
Operating Income
38.6M
15.82%
Net Income
22.5M
9.22%
Balance Sheet Metrics
Total Assets
1.3B
Total Liabilities
401.4M
Shareholders Equity
870.2M
Debt to Equity
0.46
Cash Flow Metrics
Operating Cash Flow
101.6M
Free Cash Flow
126.0M
Revenue & Profitability Trend
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Harmony Biosciences Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 868.5M | 714.7M | 582.0M | 437.9M | 305.4M |
| Cost of Goods Sold | 198.3M | 156.8M | 121.2M | 83.5M | 55.5M |
| Gross Profit | 670.1M | 557.9M | 460.8M | 354.4M | 249.9M |
| Gross Margin % | 77.2% | 78.1% | 79.2% | 80.9% | 81.8% |
| Operating Expenses | |||||
| Research & Development | 189.6M | 145.8M | 76.1M | 70.9M | 30.4M |
| Selling, General & Administrative | 272.0M | 221.3M | 192.7M | 163.3M | 132.0M |
| Other Operating Expenses | - | - | - | - | - |
| Total Operating Expenses | 461.6M | 367.1M | 268.8M | 234.2M | 162.4M |
| Operating Income | 208.5M | 190.8M | 192.0M | 120.2M | 87.5M |
| Operating Margin % | 24.0% | 26.7% | 33.0% | 27.4% | 28.7% |
| Non-Operating Items | |||||
| Interest Income | 21.9M | 18.5M | 14.7M | 3.1M | 224.0K |
| Interest Expense | 14.6M | 17.5M | 23.8M | 18.8M | 24.2M |
| Other Non-Operating Income | -680.0K | -68.0K | -9.6M | 169.0K | -26.1M |
| Pre-tax Income | 215.1M | 191.8M | 173.4M | 104.7M | 37.4M |
| Income Tax | 56.4M | 46.3M | 44.5M | -76.8M | 2.8M |
| Effective Tax Rate % | 26.2% | 24.1% | 25.7% | -73.3% | 7.6% |
| Net Income | 158.7M | 145.5M | 128.9M | 181.5M | 34.6M |
| Net Margin % | 18.3% | 20.4% | 22.1% | 41.4% | 11.3% |
| Key Metrics | |||||
| EBITDA | 255.0M | 233.4M | 231.3M | 146.9M | 106.6M |
| EPS (Basic) | $2.76 | $2.56 | $2.17 | $3.07 | $0.60 |
| EPS (Diluted) | $2.71 | $2.51 | $2.13 | $2.97 | $0.58 |
| Basic Shares Outstanding | 57492277 | 56885455 | 59469648 | 59173121 | 57531540 |
| Diluted Shares Outstanding | 57492277 | 56885455 | 59469648 | 59173121 | 57531540 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Harmony Biosciences Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 752.5M | 453.0M | 311.7M | 243.8M | 234.3M |
| Short-term Investments | 22.8M | 14.2M | 41.8M | 79.3M | 0 |
| Accounts Receivable | 96.8M | 83.0M | 74.1M | 54.7M | 34.8M |
| Inventory | 5.4M | 7.2M | 5.4M | 4.3M | 4.4M |
| Other Current Assets | 13.5M | 8.1M | 5.5M | 8.8M | 3.2M |
| Total Current Assets | 907.0M | 579.3M | 451.1M | 400.3M | 284.4M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | - | - | - | - | - |
| Goodwill | 89.4M | 113.3M | 137.1M | 161.0M | 143.9M |
| Intangible Assets | - | - | 137.1M | 161.0M | 143.9M |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 168.1M | 196.6M | 150.7M | 89.5M | 4.3M |
| Total Non-Current Assets | 364.6M | 419.9M | 360.4M | 273.6M | 149.0M |
| Total Assets | 1.3B | 999.2M | 811.4M | 673.9M | 433.4M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 17.7M | 13.7M | 17.7M | 3.8M | 1.0M |
| Short-term Debt | 20.0M | 16.2M | 15.0M | 2.0M | 2.0M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 5.0M | 5.7M | 7.8M | 1.6M | 1.4M |
| Total Current Liabilities | 252.1M | 175.1M | 163.8M | 78.9M | 53.8M |
| Non-Current Liabilities | |||||
| Long-term Debt | 143.7M | 163.0M | 178.6M | 189.6M | 190.0M |
| Deferred Tax Liabilities | - | - | - | - | - |
| Other Non-Current Liabilities | 5.6M | 1.9M | 2.1M | 2.5M | 3.2M |
| Total Non-Current Liabilities | 149.3M | 165.0M | 180.7M | 192.1M | 193.2M |
| Total Liabilities | 401.4M | 340.0M | 344.5M | 271.0M | 246.9M |
| Equity | |||||
| Common Stock | 1.0K | 1.0K | 1.0K | 1.0K | 1.0K |
| Retained Earnings | 160.9M | 2.2M | -143.3M | -272.1M | -453.6M |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 870.2M | 659.2M | 467.0M | 402.8M | 186.5M |
| Key Metrics | |||||
| Total Debt | 163.7M | 179.3M | 193.6M | 191.6M | 192.0M |
| Working Capital | 654.9M | 404.2M | 287.3M | 321.4M | 230.7M |
Balance Sheet Composition
Harmony Biosciences Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | 158.7M | 145.5M | 128.9M | 181.5M | 34.6M |
| Depreciation & Amortization | 25.3M | 24.1M | 24.4M | 23.4M | 18.8M |
| Stock-Based Compensation | 44.9M | 42.6M | 31.7M | 26.2M | 15.7M |
| Working Capital Changes | 60.0M | -4.3M | -11.5M | -17.1M | -15.0M |
| Operating Cash Flow | 317.9M | 225.1M | 165.8M | 131.9M | 56.7M |
| Investing Activities | |||||
| Capital Expenditures | -310.0K | -1.2M | -312.0K | -172.0K | -298.0K |
| Acquisitions | -19.2M | -33.1M | -37.0M | 0 | 0 |
| Investment Purchases | -86.2M | -105.3M | -127.5M | -110.7M | 0 |
| Investment Sales | 81.1M | 98.5M | 118.3M | 9.1M | 0 |
| Investing Cash Flow | -39.6M | -67.5M | -46.4M | -101.8M | -298.0K |
| Financing Activities | |||||
| Share Repurchases | 0 | 0 | -100.0M | 0 | 0 |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | 0 | 0 | 200.0M | 0 | 200.0M |
| Debt Repayment | -16.2M | -15.0M | -201.2M | -2.0M | -200.5M |
| Financing Cash Flow | -19.3M | -17.5M | -110.6M | -2.0M | -2.0M |
| Free Cash Flow | 347.9M | 218.7M | 219.1M | 104.3M | -1.7M |
| Net Change in Cash | 259.0M | 140.1M | 8.7M | 28.0M | 54.5M |
Cash Flow Trend
Harmony Biosciences Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
11.78
Forward P/E
5.58
Price to Book
2.12
Price to Sales
2.13
PEG Ratio
-0.21
Profitability Ratios
Profit Margin
18.27%
Operating Margin
15.82%
Return on Equity
20.75%
Return on Assets
11.48%
Financial Health
Current Ratio
3.60
Debt to Equity
19.45
Beta
0.89
Per Share Data
EPS (TTM)
$2.71
Book Value per Share
$15.08
Revenue per Share
$15.11
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| HRMY | 1.9B | 11.78 | 2.12 | 20.75% | 18.27% | 19.45 |
| Vertex | 109.4B | 28.40 | 5.92 | 22.54% | 32.94% | 10.91 |
| Regeneron | 81.0B | 18.00 | 2.45 | 14.86% | 31.41% | 9.51 |
| Recursion | 1.9B | -2.44 | 1.64 | -59.54% | 4.45% | 6.89 |
| Capricor | 2.0B | -15.61 | 6.62 | -46.56% | 0.00% | 4.75 |
| Zymeworks | 2.0B | 3.79 | 7.32 | -26.72% | -76.56% | 6.80 |
Financial data is updated regularly. All figures are in the company's reporting currency.






